glp 1 botox Aesthetic restoration following GLP-1 agonist–induced facial volume loss A new study suggests GLP-1

The Australian and New Zealand College of Anaesthetists (ANZCA), the Gastroenterological Society of Australia, the Australian Diabetes Society, and the National Association of Clinical Obesity Services and Australian and New Zealand Metabolic and the Obesity Surgery Society have developed revised recommendations for patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation

Understanding this timeline helps set realistic expectations and supports treatment adherence during the critical early months of therapy

Methods A comprehensive literature search was conducted to synthesize the current preclinical and clinical evidence

As the GLP-1 pathways also modulate such responses (Vestlund and Jerlhag, 2020a